Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
04 November 2021 - 9:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number: 001-40712
Cardiol Therapeutics Inc.
(Name of registrant)
602-2265 Upper Middle Road East
Oakville, Ontario L6H 0G5
Canada
(Address of
principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
INCORPORATION BY REFERENCE
Exhibit 99.1 to this report on Form 6-K
is hereby incorporated by reference as Exhibits to the Registration Statement on Form F-10 of Cardiol Therapeutics Inc. (File No. 333-257764),
as amended and supplemented.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CARDIOL THERAPEUTICS INC.
|
|
(Registrant)
|
|
|
|
Date: November 3, 2021
|
By:
|
/s/ Chris Waddick
|
|
|
Name:
|
Chris Waddick
|
|
|
Title:
|
Chief Financial Officer
|
Form 6-K Exhibit Index
Cardiol Therapeutics (NASDAQ:CRDL)
Historical Stock Chart
From Apr 2024 to May 2024
Cardiol Therapeutics (NASDAQ:CRDL)
Historical Stock Chart
From May 2023 to May 2024